News

AIRFLOW-3 Trial of Targeted Lung Denervation Assigns 100th Patient

One hundred patients have been randomly assigned in Nuvaira’s pivotal AIRFLOW-3 clinical trial that will investigate the efficacy and safety of targeted lung denervation (TLD) to reduce exacerbations, or episodes of symptom worsening, of chronic obstructive pulmonary disease (COPD) in patients on optimal medical care. Because of the…

Partnership Seeks to Lower Costs of COPD Meds

GoodRx, a platform for healthcare savings in the U.S., and pharmaceutical company Boehringer Ingelheim have teamed up to help lower out-of-pocket medication costs  for people with chronic obstructive pulmonary disease (COPD) or type 2 diabetes. Patients will be able to enroll in sponsored copay programs to access  Boehringer…

Mepolizumab Lessens Exacerbations, Improves Quality of Life

Treatment with mepolizumab, an antibody designed to lower the levels of eosinophils — immune cells linked with worse chronic obstructive pulmonary disease (COPD) — was found to reduce the annual rate of exacerbations and improve health-related quality of life in people with eosinophil-associated COPD. The findings, from a meta-analysis…